- Home
- RAPT vs INBX Comparison
RAPT vs INBX Comparison
Compare RAPT & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RAPT | INBX |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 498.4M | 430.2M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RAPT | INBX |
|---|---|---|
| Price | $35.21 | $72.36 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 2 |
| Target Price | ★ $57.00 | N/A |
| AVG Volume (30 Days) | ★ 365.9K | 218.5K |
| Earning Date | 03-05-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,400,000.00 |
| Revenue This Year | N/A | $563.00 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.67 | $10.81 |
| 52 Week High | $42.39 | $94.57 |
Technical Indicators
Market Signals| Indicator | RAPT | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 55.37 | 41.77 |
| Support Level | $33.01 | $69.47 |
| Resistance Level | $35.42 | $76.47 |
| Average True Range (ATR) | 2.17 | 4.77 |
| MACD | 0.03 | -0.76 |
| Stochastic Oscillator | 83.95 | 20.55 |
Price Performance
Historical ComparisonAbout RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.